{"entity":{"id":"elritercept","kind":"drug","name":"Elritercept","aka":["TAK-226"],"tldr":"Elritercept is Keros and Takeda's ligand trap for the anaemia of myelodysplastic syndromes, a relative of luspatercept, in phase 3 trials.","summary":"Keros Therapeutics designed elritercept (KER-050) to release the brake that activin-class ligands put on erythropoiesis and thrombopoiesis; Takeda licensed it in 2024 as TAK-226. Phase 2 data showed transfusion independence in lower-risk myelodysplastic syndromes including patients with ring sideroblasts, and phase 3 trials in transfusion-dependent lower-risk MDS are registered. Luspatercept is the approved comparator in the class.","status":"phase-3","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Elritercept","url":"https://clinicaltrials.gov/search?intr=KER-050"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["mds"],"sections":[],"technologies":["cytokine-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06499285"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, curated)","editedOn":"2026-09-16"},"code":"KER-050","modality":"Activin receptor type IIA ligand trap (fusion protein), subcutaneous","mechanism":"Binds TGF-beta family ligands such as activin A and GDF11 that hold back red cell and platelet precursors, freeing late-stage blood cell production in ineffective haematopoiesis.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/elritercept/","neighbours":{"cancer":[{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"technology":[{"id":"cytokine-therapy","kind":"technology","name":"Cytokines & engineered cytokines","route":"/technologies/cytokine-therapy/"}],"trial":[{"id":"nct06499285","kind":"trial","name":"A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular B","route":"/trials/nct06499285/"}]}}